Leveraging GNR Gold Nanorod
Sona’s GNR technology in Siva Therapeutics’
Pioneered by
Len Pagliaro, PhD
- 24 years of experience
- Successful commercialization of biotechnology products, services, and licensing
- Completed prestigious assessment program at the US Nanotechnology Characterization Laboratory (Established by the FDA and the National Cancer Institute)
Sona GNRs in targeted hyperthermia may create the opportunity to treat cancer without doing significant harm to healthy cells
Current Cancer Treatments are risky, expensive and can do harm
- Chemotherapy and radiotherapy are non-selective in their destruction of cells;
- Advanced therapies are expensive;
- Surgery is risky.
How does THT work?
- Targets heat directly to the tumor;
- Uses IV injection of GNRs to heat the tumor from the inside;
- Achieves hyperthermia instead of ablation destroying cancerous cells selectively;
- Sona GNRs are inert and do not use toxic CTAB.
Targeted Hyperthermia Therapy™ (THT)
Medical device with two components:
- Gold nanorods for injection
- Infrared light source
Heating tumors does the following:
- Stimulates immune system
- Kills cancer cells
- Increases tumor perfusion
- Shrinks tumors
Siva’s Unique Differentiator:
Selective ‘Hyperthermia’ Minimizes Collateral Damage
- THT photothermal cancer therapy using GNRs will address current treatment issues.
- Siva's THT "inside-out" heating maximizes efficacy and minimizes collateral damage.
- Siva has had major success in reducing tumors in small animal studies.
- Eliminated tumors in mice in 4 weeks
- Validated by Nanotechnology Characterization Laboratory study and report.
THT photothermal cancer therapy using GNRs will address current treatment issues
First THT Application: Colorectal Cancer Tumors
Why is THT uniquely suited for colorectal cancer treatment?
- Alternatives diminish quality of life
- Significant market
- Outpatient procedure within current workflow
- Effective for solid tumors
- Early detection is possible
- THT can be integrated with “watch and wait” approach
- Low metastatic index
Treatment Benefits:
- Minimally invasive
- Targeted treatment
- Enhances success of other cancer therapies
- Easy to use
- Affordable
Read More About Targeted Hyperthermia
- Preclinical Small Animal Study Success
- First THT Application: Colorectal Cancer Tumors
Road to Commercialization
Potential future clinical studies to provide multiple valuation catalysts.
Additionnal Publications
Sona Nanotech’s THT Cancer Studies Demonstrates Strong Efficacy in Third Preclinical Study and Plans for First-in-human Early Feasibility Study
Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the “Company”, “Sona”) announces results from its most recent preclinical study of its Targeted Hyperthermia Therapy (“THT”) which uses the Company’s patented, biocompatible gold nanorods (“GNRs”) to treat certain solid cancer tumors, shrinking them and acting as an immune stimulator. Building on its success in melanoma and breast cancer studies, the Company’s third preclinical efficacy study was conducted in an immunologically ‘cold’ colorectal cancer model (“CT26”), a model that represents the majority of human colon cancers, which do not typically respond to current standard of care immunotherapies.